Pharmaceutical dosage forms contain both pharmacologically active compounds and excipients added to aid the formulation and manufacture of the subsequent dosage form for administration to patients. Indeed, the properties of the final dosage form (i.e. its bioavailability and stability) are, for the most part, highly dependent on the excipients chosen, their concentration and interaction with both the active compound and each other. No longer can excipients be regarded simply as inert or inactive ingredients, and a detailed knowledge not only of the physical and chemical properties but also of the safety, handling and regulatory status of these materials is essential for formulators throughout the world. In addition, the growth of novel forms of delivery has resulted in an increase in the number of the excipients being used and suppliers of excipients have developed novel coprocessed excipient mixtures and new physical forms to improve their properties. The Handbook of Pharmaceutical Excipients has been conceived as a systematic, comprehensive resource of information ​ on all of these topics. URI http://repositorio.ub.edu.ar/handle/123456789/5143 Collections Libros Farmacia www.ub.edu.ar | biblioteca.ub.edu.ar Contact Us | Send Feedback Handbook of pharmaceutical excipients 

Handbook of Pharmaceutical Excipients

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jps.10005

Prediction of pharmacokinetics prior to In vivo studies. 1. Mechanism-based prediction of volume of distribution

The rapid integration of new technologies by the pharmaceutical industry has resulted in numerous breakthroughs in the discovery, development and manufacturing of pharmaceutical products In particular, the commercial-scale production of high-purity recombinant proteins has resulted in important additions to treatment options for many large therapeutic areas In addition to proteins, other macromolecules, such as the animal-derived mucopolysaccharide heparins, have also seen dramatic growth as injectable pharmaceutical products To date, macromolecules have been limited as therapeutics by the fact that they cannot be orally delivered This article will address the current status and future possibilities of oral macromolecular drug delivery

Challenges for the oral delivery of macromolecules

3D printing in pharmaceutics: A new tool for designing customized drug delivery systems

Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review

Optimisation and characterisation of bioadhesive controlled release tetracycline microspheres.

Background Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment. Objective We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha reductase inhibitor) and placebo in men with androgenetic alopecia. Methods Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes. Results In total, 917 men were randomized. Hair count and width increased dose dependently with dutasteride. Dutasteride 0.5 mg significantly increased hair count and width in a 2.54-cm diameter and improved hair growth (frontal view; panel photographic assessment) at week 24 compared with finasteride ( P  = .003, P  = .004, and P  = .002, respectively) and placebo (all P Limitations The study was limited to 24 weeks. Conclusions Dutasteride increased hair growth and restoration in men with androgenetic alopecia and was relatively well tolerated.

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.

Biomembrane Permeation of Nicotine: Mechanistic Studies with Porcine Mucosae and Skin

Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein.

Orally dissolving films

Conventional insulin therapies involve multiple daily subcutaneous injections. However, the resultant disposition of insulin and blood glucose differs considerably from that following the physiological secretion of pancreatic insulin. A variety of alternative routes/methods have been investigated to improve systemic insulin delivery. Peroral and nasal insulin administration have demonstrated good potential for the treatment of diabetes. Facilitated transdermal delivery has also enjoyed success in promoting the systemic delivery of insulin. In addition, pulmonary, buccal, and ocular insulin administration have been shown to decrease serum glucose concentrations. Other methods that have been investigated for their potential in systemic insulin delivery include rectal, vaginal, and uterine routes.

Dushendra J. Chetty

Papers

Optimisation and characterisation of bioadhesive controlled release tetracycline microspheres.

A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.

Biomembrane Permeation of Nicotine: Mechanistic Studies with Porcine Mucosae and Skin

Orally dissolving films

Novel methods of insulin delivery: an update.